P47.06 TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC

Few treatment options are available for patients with advanced/metastatic NSCLC without actionable genomic alterations that has progressed on standard therapies. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Results from a phase 1 study (TROPION-PanTumor01) in advanced/metastatic NSCLC support evaluation of Dato-DXd as a potential treatment option for these patients.